A detailed history of Harbor Capital Advisors, Inc. transactions in Kymera Therapeutics, Inc. stock. As of the latest transaction made, Harbor Capital Advisors, Inc. holds 40,303 shares of KYMR stock, worth $1.64 Million. This represents 0.08% of its overall portfolio holdings.

Number of Shares
40,303
Previous 31,011 29.96%
Holding current value
$1.64 Million
Previous $926,000 106.05%
% of portfolio
0.08%
Previous 0.07%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 29, 2024

BUY
$30.16 - $52.4 $280,246 - $486,900
9,292 Added 29.96%
40,303 $1.91 Million
Q2 2024

Jul 09, 2024

SELL
$29.85 - $39.42 $308,081 - $406,853
-10,321 Reduced 24.97%
31,011 $926,000
Q1 2024

May 13, 2024

BUY
$22.9 - $43.57 $153,223 - $291,526
6,691 Added 19.32%
41,332 $1.66 Million
Q4 2023

Jan 08, 2024

SELL
$10.97 - $26.84 $6,252 - $15,298
-570 Reduced 1.62%
34,641 $881,000
Q3 2023

Oct 20, 2023

BUY
$13.9 - $23.88 $53,292 - $91,555
3,834 Added 12.22%
35,211 $489,000
Q2 2023

Jul 11, 2023

BUY
$22.4 - $34.92 $449,321 - $700,460
20,059 Added 177.23%
31,377 $721,000
Q1 2023

Apr 26, 2023

SELL
$24.84 - $38.75 $8,942 - $13,950
-360 Reduced 3.08%
11,318 $335,000
Q4 2022

Jan 20, 2023

SELL
$19.57 - $30.92 $4,833 - $7,637
-247 Reduced 2.07%
11,678 $0
Q3 2022

Oct 28, 2022

SELL
$20.91 - $34.27 $7,109 - $11,651
-340 Reduced 2.77%
11,925 $260,000
Q2 2022

Jul 26, 2022

SELL
$14.13 - $42.55 $24,444 - $73,611
-1,730 Reduced 12.36%
12,265 $241,000
Q1 2022

Apr 28, 2022

SELL
$35.3 - $64.68 $100,816 - $184,726
-2,856 Reduced 16.95%
13,995 $592,000
Q4 2021

Feb 04, 2022

BUY
$49.91 - $65.56 $841,033 - $1.1 Million
16,851 New
16,851 $1.07 Million

Others Institutions Holding KYMR

About Kymera Therapeutics, Inc.


  • Ticker KYMR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 54,705,800
  • Market Cap $2.22B
  • Description
  • Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunolo...
More about KYMR
Track This Portfolio

Track Harbor Capital Advisors, Inc. Portfolio

Follow Harbor Capital Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Harbor Capital Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Harbor Capital Advisors, Inc. with notifications on news.